José de la Fuente Selected Research

Tick-Borne Diseases (Tick-Borne Disease)

1/2022	Oral vaccine formulation combining tick Subolesin with heat inactivated mycobacteria provides control of cross-species cattle tick infestations.
1/2022	A Quantum Vaccinomics Approach Based on Protein-Protein Interactions.
4/2021	Tick Importin-α Is Implicated in the Interactome and Regulome of the Cofactor Subolesin.
6/2020	Vaccination with Recombinant Subolesin Antigens Provides Cross-Tick Species Protection in Bos indicus and Crossbred Cattle in Uganda.
1/2020	Modeling tick vaccines: a key tool to improve protection efficacy.
1/2019	A Vaccinomics Approach for the Identification of Tick Protective Antigens for the Control of Ixodes ricinus and Dermacentor reticulatus Infestations in Companion Animals.
1/2019	Oral Vaccination With a Formulation Combining Rhipicephalus microplus Subolesin With Heat Inactivated Mycobacterium bovis Reduces Tick Infestations in Cattle.
1/2018	Controlling ticks and tick-borne diseases…looking forward.
1/2018	Rhipicephalus bursa Sialotranscriptomic Response to Blood Feeding and Babesia ovis Infection: Identification of Candidate Protective Antigens.
12/2017	Targeting a global health problem: Vaccine design and challenges for the control of tick-borne diseases.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

José de la Fuente Research Topics

Disease

85	Infections 10/2022 - 05/2002
55	Tick Infestations 01/2022 - 03/2003
23	Anaplasmosis 01/2021 - 07/2002
20	Tick-Borne Diseases (Tick-Borne Disease) 01/2022 - 12/2008
13	Communicable Diseases (Infectious Diseases) 01/2022 - 11/2009
13	Tick Bites 01/2021 - 10/2015
11	Hypersensitivity (Allergy) 01/2021 - 10/2015
10	red meat allergy 01/2021 - 01/2018
8	Anaphylaxis (Anaphylactic Shock) 01/2021 - 03/2017
8	Tuberculosis (Tuberculoses) 10/2018 - 01/2007
7	COVID-19 10/2022 - 01/2020
5	Malaria 04/2021 - 12/2014
4	Lyme Disease (Disease, Lyme) 01/2021 - 05/2005
4	Vector Borne Diseases 07/2019 - 03/2013
4	Bacterial Infections (Bacterial Infection) 07/2016 - 01/2013
3	Babesiosis (Piroplasmosis) 01/2021 - 01/2015
3	Bovine Tuberculosis 01/2017 - 05/2009
2	Inflammation (Inflammations) 01/2021 - 03/2006
2	Bites and Stings (Sting) 09/2019 - 08/2019
2	Persistent Infection 02/2010 - 06/2005
1	Aspergillosis 01/2022
1	Avian Malaria 01/2022
1	Emerging Communicable Diseases (Emerging Infectious Diseases) 12/2021
1	Tularemia 01/2021
1	Food Hypersensitivity (Food Allergy) 01/2021
1	Hyperplasia 01/2021
1	Parasitic Diseases (Parasitic Disease) 12/2020
1	Lice Infestations (Pediculosis) 01/2020
1	Disease Progression 01/2020
1	Crimean Hemorrhagic Fever 01/2019
1	Delayed Hypersensitivity (Hypersensitivity, Type IV) 01/2019
1	Alzheimer Disease (Alzheimer's Disease) 01/2019
1	Virus Diseases (Viral Diseases) 01/2019

Drug/Important Bio-Agent (IBA)

69	VaccinesIBA 01/2022 - 03/2003
51	AntigensIBA 01/2022 - 10/2002
43	Proteins (Proteins, Gene)FDA Link 01/2021 - 02/2003
18	AntibodiesIBA 01/2022 - 02/2003
16	Immunoglobulin E (IgE)IBA 01/2021 - 10/2015
12	CarbohydratesIBA 01/2022 - 10/2015
11	AcaricidesIBA 02/2021 - 08/2003
9	Immunoglobulin M (IgM)IBA 01/2021 - 10/2015
9	Arthropod ProteinsIBA 04/2019 - 06/2005
8	Immunoglobulin G (IgG)IBA 01/2021 - 10/2013
8	Membrane Proteins (Integral Membrane Proteins)IBA 01/2017 - 12/2002
7	Glycoproteins (Glycoprotein)IBA 01/2021 - 07/2008
7	ProteomeIBA 01/2020 - 01/2015
6	Messenger RNA (mRNA)IBA 01/2019 - 09/2007
5	Polysaccharides (Glycans)IBA 01/2021 - 04/2020
5	Biological ProductsIBA 02/2020 - 11/2008
5	Recombinant ProteinsIBA 03/2011 - 02/2003
4	CytokinesIBA 10/2022 - 01/2013
4	tick subolesinIBA 01/2022 - 03/2011
4	RNA (Ribonucleic Acid)IBA 05/2021 - 03/2006
4	tert-butylserineIBA 04/2021 - 12/2017
4	Peptides (Polypeptides)IBA 01/2021 - 08/2005
3	Biomarkers (Surrogate Marker)IBA 01/2021 - 01/2012
3	GlycolipidsIBA 01/2021 - 01/2020
3	Complement System Proteins (Complement)IBA 07/2020 - 10/2013
3	Amino Acids FDA Link 01/2017 - 03/2004
3	Glucose (Dextrose)FDA LinkGeneric 01/2017 - 12/2015
3	Inactivated VaccinesIBA 02/2010 - 10/2002
2	Immunologic Adjuvants (Immunologic Adjuvant)IBA 01/2022 - 01/2019
2	Anti-Bacterial Agents (Antibiotics)IBA 06/2021 - 07/2002
2	Salivary Proteins and PeptidesIBA 01/2021 - 01/2018
2	InflammasomesIBA 01/2021 - 07/2020
2	OligosaccharidesIBA 01/2021 - 04/2020
2	Blood Group Antigens (Blood Groups)IBA 01/2020 - 01/2019
2	Cetuximab (Erbitux)FDA Link 04/2019 - 10/2015
2	DefensinsIBA 01/2018 - 12/2008
2	PorinsIBA 07/2016 - 01/2015
2	NucleotidesIBA 11/2015 - 05/2007
2	Silk FDA Link 01/2014 - 12/2013
2	DNA (Deoxyribonucleic Acid)IBA 07/2008 - 03/2006
2	nucleotidaseIBA 11/2005 - 08/2005
2	Merozoite Surface Protein 1 (MSA1)IBA 03/2004 - 02/2003
1	Environmental Pollutants (Pollutants, Environmental)IBA 10/2022
1	Vehicle Emissions (Emissions, Vehicle)IBA 10/2022
1	3-Hydroxybutyric Acid (beta-Hydroxybutyric Acid)IBA 01/2022
1	Therapeutic UsesIBA 01/2022
1	feralIBA 12/2021
1	NeuropeptidesIBA 01/2021
1	TachykininsIBA 01/2021
1	EpitopesIBA 01/2021
1	AllergensIBA 01/2021
1	Blood Proteins (Serum Proteins)IBA 01/2021
1	Interleukin-8 (Interleukin 8)IBA 07/2020
1	Superoxide DismutaseIBA 07/2020
1	Interleukin 1 Receptor Antagonist Protein (Anakinra)FDA Link 07/2020
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 07/2020
1	Interleukin-17 (Interleukin 17)IBA 07/2020
1	Immunoglobulins (Immunoglobulin)IBA 04/2020
1	Toll-Like Receptors (Toll-Like Receptor)IBA 01/2020
1	Histamine (Histamine Dihydrochloride)FDA Link 01/2019
1	Detergents (Detergent)IBA 01/2019
1	Amyloid (Amyloid Fibrils)IBA 01/2019
1	PrionsIBA 01/2019
1	Transcription Factors (Transcription Factor)IBA 01/2019
1	NADPH Oxidases (NAD(P)H oxidase)IBA 01/2019
1	MicroRNAs (MicroRNA)IBA 01/2019

Therapy/Procedure

1	Oral Administration 01/2022